A 66-year-old with HFrEF (LVEF 28%) on lisinopril and furosemide remains symptomatic. No contraindications. Which addition provides mortality benefit ...

Question

A 66-year-old with HFrEF (LVEF 28%) on lisinopril and furosemide remains symptomatic. No contraindications. Which addition provides mortality benefit and is part of guideline-directed quadruple therapy?

Accepted Answer

Empagliflozin

Answer

Diltiazem extended-release

Answer

Ivabradine first-line instead of beta-blocker

Answer

Sacubitril/valsartan plus discontinue ACEI only if eGFR

Answer

Amlodipine

us-abim MCQ (SBA): Heart Failure (HFrEF)

A 66-year-old with HFrEF (LVEF 28%) on lisinopril and furosemide remains symptomatic. No contraindications. Which addition provides mortality benefit and is part of guideline-directed quadruple therapy?